Alloimmunization as a barrier to gene therapy in sickle cell disease

• DOI: 10.1111/trf.18266
• Publication Date: 2025-05-01T02:06:39Z
• Authors: Hannah R. Abrams; Nabiha H. Saifee; William S. Miller; Antonio Cortez; Rida A. Hasan; Sandhya R. Panch; Kleber Y. Fertrin
• Keywords: Transfusion Therapy

Abstract Alloimmunization is prevalent in patients with sickle cell disease (SCD) and can be a barrier to gene therapy (GT) due the necessary transfusion support for successful stem collection infusion. We estimate that standard‐of‐care GT an adult SCD will require average of 35–45 units red blood cells over 6‐month period. Institutions should actively plan these needs share information inform national consensus policies on management alloimmunization during GT.